IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC

被引：3
|
作者：
Vallieres, Eric [1 ]
Felip, Enriqueta [2 ]
Altorki, Nasser [3 ]
Zhou, Caicun [4 ]
Zuo, Yunxia [5 ]
Howland, Michael [6 ]
Xia, Fan [5 ]
Hoang, Tien [6 ]
Sandler, Alan [6 ]
Wakelee, Heather [7 ]
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[4] Tongji Univ, Affiliated Shanghai Pulm Hosp, Shanghai, Peoples R China
[5] Roche China Holding Ltd, Shanghai, Peoples R China
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Stanford Canc Inst, Stanford, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 11期
关键词：
D O I：
10.1016/j.jtho.2016.09.090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS01.55
引用
收藏
页码：S304 / S304
页数：1
相关论文
共 50 条
  • [21] IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care
    Reck, Martin
    Srivastava, Minu K.
    Wakelee, Heather A.
    Felip, Enriqueta
    Altorki, Nasser K.
    Csoszi, Tibor
    Moiseyenko, Vladimir
    Akopov, Andrey
    Smolin, Alexey
    Chella, Antonio
    Vallieres, Eric
    Martinez-Marti, Alex
    Zou, Wei
    McNally, V.
    Bennett, Elizabeth
    Prizant, Hen
    Nabet, Barzin
    Ballinger, Marcus
    Gitlitz, Barbara J.
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial
    Lee, Jay M.
    Vallieres, Eric
    Ding, Beiying
    Johnson, Ann
    Bhagwakar, Jan
    Rashidi, Sanam
    Zhu, Qian
    Gitlitz, Barbara J.
    Weksler, Benny
    Costas, Kimberly
    Altorki, Nasser
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 166 (03):
  • [23] IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
    Wakelee, Heather A.
    Altorki, Nasser K.
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor O.
    Goloborodko, Oleksandr
    Rittmeyer, Achim
    Reck, Martin
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Fu, Chenqi
    Ballinger, Marcus
    Deng, Yu
    Srivastava, Minu K.
    Bennett, Elizabeth
    Gitlitz, Barbara Jenifer
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8035 - LBA8035
  • [24] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial (vol 398, pg 1344, 2021)
    Felip, Enriqueta
    Altorki, Nasser
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor
    Goloborodko, Oleksandr
    Luft, Alexander
    Akopov, Andrey
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Voong, David
    Wu, Fan
    Yi, Jing
    Deng, Yu
    McCleland, Mark
    Bennett, Elizabeth
    Gitlitz, Barbara
    Wakelee, Heather
    LANCET, 2021, 398 (10312): : 1686 - 1686
  • [25] Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non- mall cell lung cancer (IMpower010) (vol 113, pg 4327, 2022)
    Kenmotsu, Hirotsugu
    Sugawara, Shunichi
    Watanabe, Yasutaka
    Saito, Haruhiro
    Okada, Morihito
    Yoshikawa, Toyofumi Fengshi Chen-
    Ohe, Yuichiro
    Nishio, Wataru
    Nakagawa, Shizuka
    Nagao, Haruka
    CANCER SCIENCE, 2023, 114 (05) : 2211 - 2212
  • [26] IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
    Altorki, N. K.
    Reck, M.
    Wakelee, H.
    Felip, E.
    Vallieres, E.
    Liersch, R.
    Oizumi, S.
    Tanaka, H.
    Novello, S.
    McCune, S.
    Li, H.
    Molinero, L.
    Mueller, S.
    Bennett, E.
    Gitlitz, B. J.
    McNally, V. A.
    Ballinger, M.
    Nabet, B.
    Srivastava, M. K.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S732 - S733
  • [27] Long-Term Results of Adjuvant Chemotherapy in Completely Resected NSCLC Patients
    Wurstbauer, Karl
    Sedlmayer, Felix
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (07) : 404 - 405
  • [28] IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
    Nishio, Makoto
    Saito, Haruhiro
    Goto, Koichi
    Watanabe, Satoshi
    Sueoka-Aragane, Naoko
    Okuma, Yusuke
    Kasahara, Kazuo
    Chikamori, Kenichi
    Nakagawa, Yuki
    Kawakami, Tomohisa
    CANCER SCIENCE, 2021, 112 (04) : 1534 - 1544
  • [29] Preliminary Analysis of Adjuvant Chemotherapy with Atezolizumab in Stage I-III Resected NSCLC and Clearance of ctDNA
    Maniar, R.
    Shum, E.
    Mohindra, N. A.
    Owen, D. H.
    Ma, P. C.
    Haigentz, M., Jr.
    Hall, R. D.
    Rajguru, S. A.
    Grindheim, J.
    Schulze, K.
    Hanna, N. H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S117 - S118
  • [30] Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
    Katsurada, N.
    Tachihara, M.
    Hatakeyama, Y.
    Koyama, K.
    Yumura, M.
    Kiriu, T.
    Dokuni, R.
    Hazama, D.
    Tokunaga, S.
    Tamura, D.
    Nakata, K.
    Yamamoto, M.
    Kamiryo, H.
    Kobayashi, K.
    Tanaka, Y.
    Maniwa, Y.
    Nishimura, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S885 - S885
12345